Asma Amrani-Midoun1, Soto Romuald Kiando2, Cyrielle Treard2, Xavier Jeunemaitre3, Nabila Bouatia-Naji2. 1. Biotechnology Department, Faculty of Sciences of Nature and Life, University of Oran 1 Ahmed Benbella, Oran, Algeria. Electronic address: dr.asma.amrani@gmail.com. 2. INSERM, UMR970 Paris Cardiovascular Research Center (PARCC), Paris F-75015, France; Paris-Descartes University, Sorbonne Paris Cité, Paris 75006, France. 3. INSERM, UMR970 Paris Cardiovascular Research Center (PARCC), Paris F-75015, France; Paris-Descartes University, Sorbonne Paris Cité, Paris 75006, France; AP-HP, Department of Genetics, Hôpital Européen Georges Pompidou, Paris F-75015, France.
Abstract
BACKGROUND: Many studies have investigated the role of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in essential hypertension (EH), but with conflicting results. AIM: To determine the eventual association between 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and hypertension in a sample of Algerian population from the Oran city. METHODS: A case-control study has been performed in 154 subjects including 82 hypertensives defined as subjects with elevated systolic blood pressure SBD≥140mmHg and or sustained diastolic blood pressure DBP≥90mmHg, and 72 normotensive subjects. Polymerase chain reaction (PCR) combined with restrictive fragment length polymorphism (RFLP) was used to detect the MTHFR C677T variant. RESULTS: We observe no significant differences between allelic and genotypic frequencies between cases and controls for C677T polymorphism (OR=1.51, 95% CI=0.89-2.56, P=0.13). Analyses adjusted for age, sex and body mass index improved the association level, though the association was still not significant (30% vs. 22%, OR=1.75, 95% CI=0.95-3.24, P=0.07). CONCLUSION: This work showed that genetic polymorphism related to the MTHFR gene (C677T) is not associated with the risk of hypertension in this sample of Algerian population. Larger case-control samples are required to clearly assess the role of this genetic variant in EH.
BACKGROUND: Many studies have investigated the role of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism in essential hypertension (EH), but with conflicting results. AIM: To determine the eventual association between 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and hypertension in a sample of Algerian population from the Oran city. METHODS: A case-control study has been performed in 154 subjects including 82 hypertensives defined as subjects with elevated systolic blood pressure SBD≥140mmHg and or sustained diastolic blood pressure DBP≥90mmHg, and 72 normotensive subjects. Polymerase chain reaction (PCR) combined with restrictive fragment length polymorphism (RFLP) was used to detect the MTHFRC677T variant. RESULTS: We observe no significant differences between allelic and genotypic frequencies between cases and controls for C677T polymorphism (OR=1.51, 95% CI=0.89-2.56, P=0.13). Analyses adjusted for age, sex and body mass index improved the association level, though the association was still not significant (30% vs. 22%, OR=1.75, 95% CI=0.95-3.24, P=0.07). CONCLUSION: This work showed that genetic polymorphism related to the MTHFR gene (C677T) is not associated with the risk of hypertension in this sample of Algerian population. Larger case-control samples are required to clearly assess the role of this genetic variant in EH.
Authors: Yandiswa Y Yako; Eric V Balti; Tandi E Matsha; Anastase Dzudie; Deirdre Kruger; Eugene Sobngwi; Charles Agyemang; Andre P Kengne Journal: J Clin Hypertens (Greenwich) Date: 2018-03-09 Impact factor: 3.738